{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:39:10Z","timestamp":1788586750968,"version":"build-2803163510"},"reference-count":47,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100021201","name":"European Academy of Dermatology and Venereology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021201","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dose reduction (DR) of biologics for psoriasis is already applied in clinical practice but without clear guidelines, while dermatologists addressed the need for guidance. An international consensus may contribute to optimal implementation of biologic DR in clinical psoriasis practices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This consensus study aims for international consensus on DR of biologics in adult patients with psoriasis among dermatologists worldwide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An international, modified eDelphi consensus study was performed among dermatologists worldwide. A total of 11 statements on biologic DR were generated by the international steering committee, based on a previous literature review. Invitations were distributed via international dermatological societies. Participants rated their level of agreement per statement on a 9\u2010point Likert scale. A maximum of three consensus rounds and one (digital) consensus meeting were expected. Statements reached consensus if \u226570% agreed and &lt;15% disagreed; otherwise, statements were revised for a next consensus round.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 62 dermatologists from Europe, South America, Asia, North America, Africa and Australia completed the eDelphi. After one round, 9 out of 11 statements reached consensus. The remaining 2 statements were adapted and reached consensus in the second round. Participants agreed on criteria when to consider and initiate\/(dis)continue DR and on a two\u2010step DR algorithm for adalimumab, etanercept and ustekinumab. Participants agreed that this two\u2010step DR strategy can also be considered for IL\u201017 and IL\u201023 inhibitors while awaiting more scientific evidence on DR of these newer biologics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dermatologists worldwide reached consensus on when and how to initiate and (dis)continue DR of biologics, and on a two\u2010step DR algorithm for adalimumab, etanercept and ustekinumab in adult patients with psoriasis. DR of IL\u201017 and IL\u201023 inhibitors was deemed feasible; however, underlying evidence is still limited. This first international consensus provides essential information for uptake and implementation of biologic DR for psoriasis on a global scale.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.70447","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:39:27Z","timestamp":1776778767000},"page":"1449-1459","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["International consensus on dose reduction of biologics for patients with psoriasis: The\n                    <scp>DR<\/scp>\n                    . Delphi study"],"prefix":"10.1111","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7945-3562","authenticated-orcid":false,"given":"C. A. M.","family":"van Riel","sequence":"first","affiliation":[{"name":"Department of Dermatology Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.\u2010H.","family":"Boehncke","sequence":"additional","affiliation":[{"name":"Division of Dermatology and Venereology, Department of Pathology and Immunology, and University Hospitals of Geneva University of Geneva  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5303-9310","authenticated-orcid":false,"given":"J. L. W.","family":"Lambert","sequence":"additional","affiliation":[{"name":"Department of Dermatology Ghent University Hospital  Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. I.","family":"Spuls","sequence":"additional","affiliation":[{"name":"Department of Dermatology Amsterdam Public Health\/Infection and Immunology  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. S.","family":"van der Schoot","sequence":"additional","affiliation":[{"name":"Department of Dermatology Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"van Ee","sequence":"additional","affiliation":[{"name":"Dutch Psoriasis Patients Federation (\u2018Psoriasispati\u00ebnten Nederland\u2019)  Nijkerk The Netherlands"},{"name":"International Federation of Psoriatic Disease Associations  Bromma Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3872-5704","authenticated-orcid":false,"given":"E. M. G. J.","family":"de Jong","sequence":"additional","affiliation":[{"name":"Department of Dermatology Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3642-2673","authenticated-orcid":false,"given":"J. M. P. A.","family":"van den Reek","sequence":"additional","affiliation":[{"name":"Department of Dermatology Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the eDelphi consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04290.x"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12543"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2015.06.004"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2209"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1088127"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000420"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.4897"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3815"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1869147"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1759769"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2571"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15722"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04610.x"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14826"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1369805"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21797"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-021-02273-4"},{"issue":"1","key":"e_1_2_13_19_1","first-page":"22","article-title":"Dosisvermindering van biologics voor psoriasis","volume":"31","author":"Muijen ME","year":"2021","journal-title":"Ned Tijdschr Dermatol Venereol"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1832649"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004390"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01448-z"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2154570"},{"key":"e_1_2_13_24_1","unstructured":"Castor EDC.Castor Electronic Data Capture 2019. [cited 2019 Aug 27]. Available from:https:\/\/castoredc.com."},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-016-1765-7"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3751"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16672"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13599"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12677"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv096"},{"issue":"8","key":"e_1_2_13_32_1","article-title":"Long\u2010term dose optimization of adalimumab via dose spacing in patients with psoriasis","volume":"9","author":"Benzaquen M","year":"2022","journal-title":"Bioengineering Basel"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2043546"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18143"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01280-9"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.2463"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16915"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00894-9"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2492197"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.70062"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.70122"},{"issue":"7","key":"e_1_2_13_43_1","article-title":"Sustained efficacy and safety of tildrakizumab in psoriasis vulgaris despite multiple prolonged treatment interruptions: a case report","volume":"17","author":"Yatsuzuka K","year":"2025","journal-title":"Cureus"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05681-z"},{"issue":"12","key":"e_1_2_13_45_1","first-page":"1584","article-title":"Down\u2010titration of infliximab: the real\u2010life use in psoriatic patients","volume":"15","author":"Bardazzi F","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16256"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-5-37"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/anae.15808"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70447","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70447","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:05:41Z","timestamp":1787670341000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/jdv.70447"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70447","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"2025-09-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}